Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ELAN 
Elanco Animal Health (ELAN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: ELAN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -15.13% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.14B USD | Price to earnings Ratio 15.22 | 1Y Target Price 15.09 |
Price to earnings Ratio 15.22 | 1Y Target Price 15.09 | ||
Volume (30-day avg) 4570600 | Beta 1.44 | 52 Weeks Range 10.03 - 18.80 | Updated Date 04/1/2025 |
52 Weeks Range 10.03 - 18.80 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 7.61% | Operating Margin (TTM) 1.37% |
Management Effectiveness
Return on Assets (TTM) 1.19% | Return on Equity (TTM) 5.49% |
Valuation
Trailing PE 15.22 | Forward PE 12.36 | Enterprise Value 9095254016 | Price to Sales(TTM) 1.17 |
Enterprise Value 9095254016 | Price to Sales(TTM) 1.17 | ||
Enterprise Value to Revenue 2.03 | Enterprise Value to EBITDA 6.51 | Shares Outstanding 496457984 | Shares Floating 491394003 |
Shares Outstanding 496457984 | Shares Floating 491394003 | ||
Percent Insiders 0.87 | Percent Institutions 100.48 |
Analyst Ratings
Rating 3.88 | Target Price 17.33 | Buy 2 | Strong Buy 6 |
Buy 2 | Strong Buy 6 | ||
Hold 8 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Elanco Animal Health
Company Overview
History and Background
Elanco Animal Health was founded in 1954 as a division of Eli Lilly and Company. It focused on animal health products and was later spun off as an independent publicly traded company in 2019. Significant milestones include acquisitions and expansion of its product portfolio.
Core Business Areas
- Companion Animal Health: Focuses on preventing and treating diseases in pets, offering parasiticides, vaccines, and therapeutics.
- Food Animal Health: Offers solutions for livestock, including poultry, swine, and cattle, to improve health, productivity, and welfare, encompassing vaccines, antimicrobials, and feed additives.
Leadership and Structure
Elanco is led by a CEO and a senior management team. Its organizational structure includes functional departments and regional business units.
Top Products and Market Share
Key Offerings
- Credelio: An oral flea and tick preventative for dogs and cats. The market share for Credelio is significant, and the drug has captured a sizable portion of the flea and tick medication market. Competitors include Bravecto (MSD Animal Health) and NexGard (Boehringer Ingelheim).
- Interceptor Plus: A broad-spectrum dewormer and heartworm preventative for dogs. Interceptor Plus has a strong market presence. Competitors include Heartgard Plus (Boehringer Ingelheim) and Revolution (Zoetis).
- Galliprant: A non-steroidal anti-inflammatory drug (NSAID) for the control of pain and inflammation associated with osteoarthritis in dogs. Galliprant is used to treat osteoarthritis. Competitors include Rimadyl (Zoetis).
Market Dynamics
Industry Overview
The animal health industry is experiencing growth driven by increasing pet ownership, rising demand for protein, and greater awareness of animal welfare.
Positioning
Elanco is positioned as a leading animal health company with a broad portfolio of products and a global presence. It aims to provide innovative solutions for both companion and food animals.
Total Addressable Market (TAM)
The global animal health market is projected to reach over $70 billion in the coming years. Elanco is positioned to capture a significant portion of this market with its diverse product offerings and global reach.
Upturn SWOT Analysis
Strengths
- Diverse product portfolio
- Global presence and distribution network
- Strong R&D capabilities
- Established brand reputation
Weaknesses
- Debt burden from acquisitions
- Exposure to regulatory changes
- Competition from larger players
- Integration challenges from acquisitions
Opportunities
- Expanding into emerging markets
- Developing innovative products
- Acquiring complementary businesses
- Leveraging digital technologies
Threats
- Generic competition
- Economic downturns affecting pet ownership
- Outbreaks of animal diseases
- Changes in consumer preferences
Competitors and Market Share
Key Competitors
- ZTS
- MRK
- BIIB
Competitive Landscape
Elanco is a major player in the animal health market, but faces competition from larger companies like Zoetis, which is a subsidiary of Pfizer.
Major Acquisitions
Bayer Animal Health
- Year: 2020
- Acquisition Price (USD millions): 7600
- Strategic Rationale: Expanded Elanco's product portfolio and global reach, making it the second-largest animal health company.
Growth Trajectory and Initiatives
Historical Growth: Elanco's growth has been driven by organic growth and acquisitions.
Future Projections: Analyst estimates vary, but generally project continued growth in revenue and earnings driven by new product launches and market expansion.
Recent Initiatives: Recent strategic initiatives include focusing on innovative products and expanding into emerging markets. Acquisitions that focus on food animal health or pet health.
Summary
Elanco Animal Health is a major player in the animal health industry with a diverse portfolio of products. It has achieved growth through strategic acquisitions, but faces challenges in managing its debt. The company benefits from strong R&D capabilities and a global presence. Elanco needs to focus on integrating acquisitions and managing its debt to continue its growth trajectory.
Similar Companies
BIIB
Biogen Inc
BIIB
Biogen Inc
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
ZTS
Zoetis Inc
ZTS
Zoetis Inc
Sources and Disclaimers
Data Sources:
- Elanco Animal Health Investor Relations
- Analyst Reports
- Market Research Reports
- Company Filings (SEC)
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may vary. Financial data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Elanco Animal Health
Exchange NYSE | Headquaters Greenfield, IN, United States | ||
IPO Launch date 2018-09-20 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 9000 | Website https://www.elanco.com |
Full time employees 9000 | Website https://www.elanco.com | ||
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus, Doncit, Drontal, Drontal Plus, and Trifexis trademarks; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. The company also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, it offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, the company offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and TruCan trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. It sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.